newsfilter
← Latest News
GlobeNewswire·

MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

  • MapLight Therapeutics, Inc. closed its initial public offering of 16,962,500 shares of common stock at $17.00 per share.
  • The offering included the full exercise of the underwriters' option to purchase an additional 2,212,500 shares.
  • A concurrent private placement of 476,707 shares was sold to affiliates of Goldman Sachs & Co. LLC at the initial public offering price.
  • Gross proceeds from the initial public offering & private placement totaled $296.3 million before deducting underwriting discounts, commissions, & offering expenses.
  • Shares began trading on the Nasdaq Global Select Market on October 27, 2025, under the symbol "MPLT".
  • Morgan Stanley, Jefferies, Leerink Partners, & Stifel served as joint book-running managers for the offering.
  • A registration statement became automatically effective with the U.S. Securities & Exchange Commission on October 25, 2025.
  • MapLight is a clinical-stage biopharmaceutical company developing ML-007C-MA, an oral fixed-dose combination currently in Phase 2 trials for schizophrenia & Alzheimer's disease psychosis.